Skip to main content
Premium Trial:

Request an Annual Quote

Native Antigen Company Inks Distribution Deals

NEW YORK — British reagent provider The Native Antigen Company said today that it has signed distribution agreements for its products covering certain European and Asian markets.

According to Native Antigen, Biozol will distribute its line of native and recombinant viral and bacterial antigens, antibodies, and immunoassays in Germany, Switzerland, and Austria. Shanghai Bioleaf will distribute the products in China.

Native Antigen specializes in the isolation and purification of native antigens and recombinant proteins from viral and bacterial pathogens in mammalian cell expression systems. The company said its products are used by pharmaceutica companies, in vitro diagnostic assay manufacturers, and academic groups for vaccine research and serology, where correct folding and glycosylation are vital.

Specific terms of the deals were not disclosed.

"Biozol and Bioleaf are both well-established distributors who have extensive local knowledge and sales infrastructure in these overseas markets which will allow us to deliver our growing range of reagents to researchers working in academia and industry," Native Antigen Commercial Director Andy Lane said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.